Meg Alexander: Company Progressing Well, Well Capitalized into 2029
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
"Our first quarter reflected focused execution and continued progress across our pipeline of potentially transformative small molecule medicines for intractable brain conditions," stated Meg Alexander, President and Chief Executive Officer. "Our development programs remain on track, our clinical organization has expanded, and we expect to be well capitalized into 2029, positioning us for multiple anticipated proof-of-concept and proof-of-signal readouts. We are especially pleased to have initiated Phase 1 dosing this month for our oral KCC2 direct activator, OV4071, alongside the expansion of OV329's development programs, as we advance therapies targeting mechanisms central to excitatory/inhibitory balance in the brain."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OVID?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OVID
Wall Street analysts forecast OVID stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.640
Low
2.00
Averages
4.17
High
7.00
Current: 2.640
Low
2.00
Averages
4.17
High
7.00
About OVID
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ovid Therapeutics Reports Q1 Results and Pipeline Updates
- Financial Performance: Ovid Therapeutics reported a Q1 GAAP EPS of -$0.12, aligning with market expectations, indicating stability in financial performance despite ongoing losses.
- Cash Reserves: As of March 31, 2026, the company held $165.6 million in cash, cash equivalents, and marketable securities, excluding $27.3 million received in April 2026 from the exercise of Series A warrants, ensuring funding for ongoing R&D efforts.
- Financing Progress: Ovid Therapeutics secured $60 million in financing to advance its OV329 epilepsy drug, which will accelerate clinical trials and enhance its competitive position in the CNS disorders market.
- Pipeline Updates: The company discussed advancements in KCC2 research and its pipeline for CNS disorders, reflecting ongoing efforts in innovative drug development aimed at addressing unmet medical needs and driving future growth.
See More
Wedbush Reiterates Ovid Therapeutics at Outperform with $7 Price Target
- Catalyst Event: Ovid Therapeutics is set to host a KCC2-focused R&D Day on April 14, 2026, which analysts believe will serve as a significant catalyst, potentially enhancing market interest in the company's CNS advancements and stock performance.
- Pipeline Development: Ovid's pipeline includes OV329 and OV4071, with the former demonstrating a favorable safety profile in Phase 1 trials, while success in the Parkinson's disease psychosis indication for OV4071 could add approximately $3 to $5 per share to the company's valuation, highlighting its market potential.
- Strong Financial Position: As of December 31, 2025, Ovid reported $90.4 million in cash and equivalents, expected to fund critical studies for OV329 and OV4071 into late 2028, with the possibility of extending the runway to 2029, thereby bolstering investor confidence.
- Market Performance Review: Ovid's stock has traded between $0.2430 and $2.72 over the past year, closing at $2.56 on Tuesday with an 11.30% increase, reflecting optimistic market sentiment regarding its future R&D potential.
See More
Ovid Therapeutics Stock Surges 18% on Positive OV329 Data
- Stock Surge: Ovid Therapeutics' stock rose over 18% as of midnight today, reflecting strong market confidence in the company's future prospects following positive news regarding its drug candidate OV329.
- Drug Development Progress: OV329, a next-generation GABA-AT inhibitor aimed at treating rare and treatment-resistant epilepsy, is believed by management to be more potent than the first-generation drug Vigabatrin, with a better safety and tolerability profile, potentially improving patient quality of life significantly.
- Clinical Trial Results: The latest Phase 1 trial results showed no treatment-related adverse events in the 7 mg cohort, and ophthalmic assessments revealed no evidence of ocular or retinal changes associated with OV329, indicating promising safety data.
- Funding Plan: The company announced a $60 million private placement intended to support the development of OV329 for other indications, including tuberous sclerosis complex seizures and infantile spasms, as well as a Phase 2 trial for focal onset seizures in drug-resistant patients, providing crucial funding for future growth.
See More
Ovid Therapeutics' OV329 Shows Promising Safety and Efficacy in Phase 1 Study
- Drug Development Progress: Ovid Therapeutics defines OV329 as a 'next-generation GABA-AT inhibitor' aimed at treating rare and treatment-resistant epilepsy and seizures, with management asserting it is more potent and safer than the first-generation drug Vigabatrin, showcasing the company's innovative potential in neurology.
- Promising Safety Data: The latest Phase 1 trial of OV329 at a 7 mg dose reported 'no treatment-related adverse events,' and ophthalmic assessments showed no evidence of ocular or retinal changes associated with OV329, establishing a solid foundation for further development.
- Funding for R&D: Ovid announced a $60 million private placement to support OV329's development in additional indications, including tuberous sclerosis complex seizures and infantile spasms, demonstrating the company's strong commitment to advancing its drug pipeline.
- Positive Stock Reaction: Ovid Therapeutics' stock rose over 18% today, reflecting market optimism regarding OV329 and indicating investor confidence in the company's potential impact on epilepsy treatment in the future.
See More
Coherent Corp. Shares Rise 6% Ahead of OFC 2026 Showcase
- Stock Performance: Coherent Corp.'s shares are climbing approximately 6% in Wednesday morning trading, currently priced at $260.86, reflecting a 6.10% increase from the opening price of $251.94, indicating strong market optimism about its future performance.
- Trading Volatility: The stock has reached a high of $265.80 during today's session, with a yearly trading range of $45.58 to $300.20, showcasing investor confidence in the company's innovative capabilities.
- Technology Showcase: The company will highlight the breadth and scalability of its Indium Phosphide (InP) innovations at OFC 2026, covering high-power lasers, advanced modulators, photodiodes, and integrated subsystems, underscoring its technological leadership in AI-driven networks.
- Strategic Commitment: By expanding its InP platform, Coherent Corp. demonstrates its commitment to delivering the performance, scalability, and manufacturing depth required to meet the growing demands of AI networks, thereby enhancing its competitive position in the market.
See More
Health Care Stocks Decline in Premarket Trading
- Market Trend: Health care stocks are generally declining in premarket trading on Wednesday, reflecting a cautious investor sentiment likely influenced by overall market emotions and economic data.
- Sector Impact: The drop in the Health Care Select Sector Index may affect the stock performance of related companies, especially amid unclear future earnings expectations from investors.
- Investor Reaction: As market volatility increases, investors may reassess the investment value of health care stocks, leading to capital outflows that further exacerbate downward pressure on stock prices.
- Economic Context: Given the heightened economic uncertainty, the performance of the health care sector may be more significantly impacted, prompting investors to closely monitor relevant policies and market dynamics.
See More
Ovid Therapeutics Reports Q1 Results and Pipeline Updates
- Financial Performance: Ovid Therapeutics reported a Q1 GAAP EPS of -$0.12, aligning with market expectations, indicating stability in financial performance despite ongoing losses.
- Cash Reserves: As of March 31, 2026, the company held $165.6 million in cash, cash equivalents, and marketable securities, excluding $27.3 million received in April 2026 from the exercise of Series A warrants, ensuring funding for ongoing R&D efforts.
- Financing Progress: Ovid Therapeutics secured $60 million in financing to advance its OV329 epilepsy drug, which will accelerate clinical trials and enhance its competitive position in the CNS disorders market.
- Pipeline Updates: The company discussed advancements in KCC2 research and its pipeline for CNS disorders, reflecting ongoing efforts in innovative drug development aimed at addressing unmet medical needs and driving future growth.
See More
Wedbush Reiterates Ovid Therapeutics at Outperform with $7 Price Target
- Catalyst Event: Ovid Therapeutics is set to host a KCC2-focused R&D Day on April 14, 2026, which analysts believe will serve as a significant catalyst, potentially enhancing market interest in the company's CNS advancements and stock performance.
- Pipeline Development: Ovid's pipeline includes OV329 and OV4071, with the former demonstrating a favorable safety profile in Phase 1 trials, while success in the Parkinson's disease psychosis indication for OV4071 could add approximately $3 to $5 per share to the company's valuation, highlighting its market potential.
- Strong Financial Position: As of December 31, 2025, Ovid reported $90.4 million in cash and equivalents, expected to fund critical studies for OV329 and OV4071 into late 2028, with the possibility of extending the runway to 2029, thereby bolstering investor confidence.
- Market Performance Review: Ovid's stock has traded between $0.2430 and $2.72 over the past year, closing at $2.56 on Tuesday with an 11.30% increase, reflecting optimistic market sentiment regarding its future R&D potential.
See More
Ovid Therapeutics Stock Surges 18% on Positive OV329 Data
- Stock Surge: Ovid Therapeutics' stock rose over 18% as of midnight today, reflecting strong market confidence in the company's future prospects following positive news regarding its drug candidate OV329.
- Drug Development Progress: OV329, a next-generation GABA-AT inhibitor aimed at treating rare and treatment-resistant epilepsy, is believed by management to be more potent than the first-generation drug Vigabatrin, with a better safety and tolerability profile, potentially improving patient quality of life significantly.
- Clinical Trial Results: The latest Phase 1 trial results showed no treatment-related adverse events in the 7 mg cohort, and ophthalmic assessments revealed no evidence of ocular or retinal changes associated with OV329, indicating promising safety data.
- Funding Plan: The company announced a $60 million private placement intended to support the development of OV329 for other indications, including tuberous sclerosis complex seizures and infantile spasms, as well as a Phase 2 trial for focal onset seizures in drug-resistant patients, providing crucial funding for future growth.
See More
Ovid Therapeutics' OV329 Shows Promising Safety and Efficacy in Phase 1 Study
- Drug Development Progress: Ovid Therapeutics defines OV329 as a 'next-generation GABA-AT inhibitor' aimed at treating rare and treatment-resistant epilepsy and seizures, with management asserting it is more potent and safer than the first-generation drug Vigabatrin, showcasing the company's innovative potential in neurology.
- Promising Safety Data: The latest Phase 1 trial of OV329 at a 7 mg dose reported 'no treatment-related adverse events,' and ophthalmic assessments showed no evidence of ocular or retinal changes associated with OV329, establishing a solid foundation for further development.
- Funding for R&D: Ovid announced a $60 million private placement to support OV329's development in additional indications, including tuberous sclerosis complex seizures and infantile spasms, demonstrating the company's strong commitment to advancing its drug pipeline.
- Positive Stock Reaction: Ovid Therapeutics' stock rose over 18% today, reflecting market optimism regarding OV329 and indicating investor confidence in the company's potential impact on epilepsy treatment in the future.
See More
Coherent Corp. Shares Rise 6% Ahead of OFC 2026 Showcase
- Stock Performance: Coherent Corp.'s shares are climbing approximately 6% in Wednesday morning trading, currently priced at $260.86, reflecting a 6.10% increase from the opening price of $251.94, indicating strong market optimism about its future performance.
- Trading Volatility: The stock has reached a high of $265.80 during today's session, with a yearly trading range of $45.58 to $300.20, showcasing investor confidence in the company's innovative capabilities.
- Technology Showcase: The company will highlight the breadth and scalability of its Indium Phosphide (InP) innovations at OFC 2026, covering high-power lasers, advanced modulators, photodiodes, and integrated subsystems, underscoring its technological leadership in AI-driven networks.
- Strategic Commitment: By expanding its InP platform, Coherent Corp. demonstrates its commitment to delivering the performance, scalability, and manufacturing depth required to meet the growing demands of AI networks, thereby enhancing its competitive position in the market.
See More
Health Care Stocks Decline in Premarket Trading
- Market Trend: Health care stocks are generally declining in premarket trading on Wednesday, reflecting a cautious investor sentiment likely influenced by overall market emotions and economic data.
- Sector Impact: The drop in the Health Care Select Sector Index may affect the stock performance of related companies, especially amid unclear future earnings expectations from investors.
- Investor Reaction: As market volatility increases, investors may reassess the investment value of health care stocks, leading to capital outflows that further exacerbate downward pressure on stock prices.
- Economic Context: Given the heightened economic uncertainty, the performance of the health care sector may be more significantly impacted, prompting investors to closely monitor relevant policies and market dynamics.
See More
